Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41


Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.

Bracken-Clarke DB, Lucas MW, Higgins MJ.

Breast Care (Basel). 2017 Jul;12(3):138-144. doi: 10.1159/000477956. Epub 2017 Jun 28. Review.


Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.

Wangchinda P, Ithimakin S.

World J Surg Oncol. 2016 Aug 24;14(1):223. doi: 10.1186/s12957-016-0988-0.


Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.

Lee ES, Han W, Kim MK, Kim J, Yoo TK, Lee MH, Lee KH, Kim TY, Moon HG, Im SA, Noh DY, Lee ES.

BMC Cancer. 2016 Jul 7;16:430. doi: 10.1186/s12885-016-2423-x.


Trial watch - inhibiting PARP enzymes for anticancer therapy.

Sistigu A, Manic G, Obrist F, Vitale I.

Mol Cell Oncol. 2015 Jun 10;3(2):e1053594. doi: 10.1080/23723556.2015.1053594. eCollection 2016 Mar. Review.


Adjuvant hormonal therapy in premenopausal women with breast cancer.

Smyth L, Hudis C.

Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):195-200. doi: 10.4103/0971-5851.171530. No abstract available.


Aromatase inhibitor treatment for breast cancer: short-term effect on bone health.

Erbağ G, Uygun K, Binnetoğlu E, Korkmaz AN, Aşık M, Şen H, Güneş F, Eroğlu M, Gökmen F, Temiz S.

Contemp Oncol (Pozn). 2015;19(5):374-7. doi: 10.5114/wo.2014.45305. Epub 2015 Aug 7.


New and emerging factors in tumorigenesis: an overview.

Kim S.

Cancer Manag Res. 2015 Jul 28;7:225-39. doi: 10.2147/CMAR.S47797. eCollection 2015. Review.


RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.

Wang J, Lu K, Song Y, Zhao S, Ma W, Xuan Q, Tang D, Zhao H, Liu L, Zhang Q.

PLoS One. 2015 Jul 28;10(7):e0133964. doi: 10.1371/journal.pone.0133964. eCollection 2015.


Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE.

J Clin Oncol. 2015 Jul 20;33(21):2353-60. doi: 10.1200/JCO.2015.60.9271. Epub 2015 Jun 15.


Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Freedman OC, Fletcher GG, Gandhi S, Mates M, Dent SF, Trudeau ME, Eisen A.

Curr Oncol. 2015 Mar;22(Suppl 1):S95-S113. doi: 10.3747/co.22.2326. Review.


Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer.

Bauerschlag DO, Maass N, Schem C.

Breast Care (Basel). 2014 Apr;9(4):283-6. doi: 10.1159/000365561. Review.


Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.

Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P, Lim B.

F1000Res. 2014 Aug 19;3:198. doi: 10.12688/f1000research.4340.1. eCollection 2014. Review.


Status of adjuvant endocrine therapy for breast cancer.

Schiavon G, Smith IE.

Breast Cancer Res. 2014;16(2):206. Review.


Long-term risk of medical conditions associated with breast cancer treatment.

Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, Kinney AY, Berg JS, Edwards KL, Moorman PG, Plon SE, Strong LC, Ziogas A, Griffin CA, Kasten CH, Finkelstein DM.

Breast Cancer Res Treat. 2014 May;145(1):233-43. doi: 10.1007/s10549-014-2928-4. Epub 2014 Apr 3.


Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.

Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E.

PLoS One. 2014 Feb 20;9(2):e88238. doi: 10.1371/journal.pone.0088238. eCollection 2014.


Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.

Schneider R, Barakat A, Pippen J, Osborne C.

Breast Cancer (Dove Med Press). 2011 Oct 4;3:113-25. doi: 10.2147/BCTT.S22905. Review.


Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

Mandelblatt JS, Hurria A, McDonald BC, Saykin AJ, Stern RA, VanMeter JW, McGuckin M, Traina T, Denduluri N, Turner S, Howard D, Jacobsen PB, Ahles T; Thinking and Living With Cancer Study.

Semin Oncol. 2013 Dec;40(6):709-25. doi: 10.1053/j.seminoncol.2013.09.006. Review.


Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93.

Pagani O, Gelber S, Colleoni M, Price KN, Simoncini E.

Breast Cancer Res Treat. 2013 Nov;142(2):455-9. doi: 10.1007/s10549-013-2757-x. Epub 2013 Nov 7.


Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.

Wang J, Lu K, Song Y, Xie L, Zhao S, Wang Y, Sun W, Liu L, Zhao H, Tang D, Ma W, Pan B, Xuan Q, Liu H, Zhang Q.

PLoS One. 2013 Jul 19;8(7):e68798. doi: 10.1371/journal.pone.0068798. Print 2013.

Supplemental Content

Support Center